Preprocedural statin administration can reduce thrombotic reaction after stent implantation

Circulation Journal

Volumn 72, Issue 2, 2008, Pages 232-237

  Nishino, Masami ^a   Hoshida, Shiro ^b   Kato, Hiroyasu ^a   Egami, Yasuyuki ^a   Shutta, Ryu ^a   Yamaguchi, Hitoshi ^a   Tanaka, Kenjiro ^a   Tanouchi, Jun ^a   Hori, Masatsugu ^b,c   Yamada, Yoshio ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

^b Yao Municipal Hospital   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherectomy; Restenosis; Statin; Stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; PRAVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIRECTIONAL ATHERECTOMY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIVARIATE ANALYSIS; RESTENOSIS; SENSITIVITY ANALYSIS; SMOOTH MUSCLE FIBER; STABLE ANGINA PECTORIS; STENT; THROMBOSIS;

AGED; ANGINA PECTORIS; ATHERECTOMY, CORONARY; CORONARY RESTENOSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PREOPERATIVE CARE; STENTS; THROMBOSIS;

EID: 40949155881     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.232     Document Type: Article

References (48)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Hayashi BE, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
3. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-794.
4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
5. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
6. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-1932.
7. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705.
8. Walter DH, Schachinger V, Elsner M, Mach S, Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000; 85: 962-968.
9. Walter DH, Schachinger V, Elsner M, Mach S, Dimmeler S, Auch-Schwelk W, et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2) allele of the platelet glycoprotein IIIa gene. Eur Heart J 2001; 22: 5870595.
10. Feldman LJ, Mazighi M, Scheuble A, Deux JF, De Benedetti E, Badier-Commander C, et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation 2001; 103: 3117-3122.
11. Lowe HC, Chesterman CN, Khachigian LM. Does thrombus contribute to in-stent restenosis in the porcine coronary stent model? Thromb Haemost 2001; 85: 1117-1118.
12. Fitzgerald PJ, Takagi A, Moore MP, Hayase M, Kolodgie FD, Corl D, et al. Intravascular sonotherapy decreases neointimal hyperplasia after stent implantation in swine. Circulation 2001; 103: 1828-1831.
13. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-58.
14. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
15. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
16. Schomig A, Mehilli J, Holle H, Hosl K, Kastrati D, Pache J, et al. Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol 2002; 40: 854-861.
17. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
18. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001; 108: 1429-1437.
19. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-678.
20. Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004; 173: 285-290.
21. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233.
22. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
23. Tanguay JF, Geoffroy P, Sirois MG, Libersan D, Kumar A, Schraub RG, et al. Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1. Thromb Haemost 2004; 91: 1186-1193.
24. Song W, Lee J, Kim H, Libersan D, Kumar A, Schaub RG, et al. A new percutaneous porcine coronary model of chronic total occlusion. J Invasive Cardiol 2005; 17: 452-454.
25. Schachinger V, Allert M, Kasper W, Just H, Vach W, Zeiher AM. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty: Results of a prospective, randomized trial. Circulation 1994; 90: 2258-2266.
26. Okura H, Morino Y, Oshima A, Hayase M, Ward MR, Popma JJ, et al. Preintervention arterial remodeling affects clinical outcome following stenting: An intravascular ultrasound study. J Am Coll Cardiol 2001; 37: 1031-1035.
27. Kotani J, Mintz GS, Castagna MT, Pinnow E, Berzingi CO, Bui AB, et al. Intravascular ultrasound analysis of infarct-related and non-infarct-related arteries in patients who presented with an acute myocardial infarction. Circulation 2003; 107: 2889-2893.
28. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
29. Cosgrave J, Melzi G, Biondi-Zoccai GG, Airoldi F, Chieffo A, Sangiorgi GM, et al. Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol 2006; 47: 2399-2404.
30. Anderson PG, Bajaj RK, Baxley WA, Roubin GS. Vascular pathology of balloon-expandable flexible coil stents in humans. J Am Coll Cardiol 1992; 19: 372-381.
31. van Beusekom HM, van der Giessen WJ, van Suylen R, Bos E, Bosman FT, Serruys PW. Histology after stenting of human saphenous vein bypass grafts: Observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993; 21: 45-54.
32. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107: 1750-1756.
33. Gaddam V, Li DY, Mehta JL. Antithrombotic effects of atorvastatin: An effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002; 7: 247-253.
34. Markle RA, Han J, Summers BD, Yokoyama T, Hajjar KA, Hajjar DP, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 2003; 90: 23-32.
35. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
36. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
37. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286: 64-70.
38. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001; 173: 139-143.
39. Miyauchi K, Kimura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, et al. Japan assessment of pravastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): Rationale and design. Circ J 2006; 70: 1624-1628.
40. Takayama T, Hiro T, Yamagishi M, Daida H, Saito S, Yamaguchi T, et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ J 2001; 71: 271-275.
41. Fenton JW 2nd, Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG. Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 115-120.
42. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 497-500.
43. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-1854.
44. Swiatkowska M, Pawlowska Z, Szemraj J, Drzewoski J, Watala C, Cierniewski CS. Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity. Jpn J Pharmacol 2002; 90: 337-344.
45. Kroger K, Lindemann M, Kreuzfelder E, Brocker M, Santosa F, Grosse-Wilde H. Effect of atorvastatin and clopidogrel on cellular immune function. Prostaglandins Leukot Essent Fatty Acids 2003; 68: 251-255.
46. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty: The PREDICT Trial Investigators: Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol 1997; 30: 863-869.
47. Kleemann A, Eckert S, von Eckardstein A, Lepper W, Schernikau U, Gleichmann U, et al. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA: The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT). Eur Heart J 1999; 20: 1393-1406.
48. Petronio AS, Amoroso G, Limbruno U, Papini B, De Carlo M, Micheli A, et al. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound. Am Heart J 2005; 149: 520-526.